RecruitingPhase 2NCT06797297

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

Studying Malignant melanoma of the mucosa

Last synced from ClinicalTrials.gov April 30, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Intervention: IBI363(biological)
Enrollment: 180 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (30)

First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing Jishuitan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Peking University Cancer Hospital & Institute, Beijing, China,, Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
The Third people's hospital of Zhengzhou, Zhengzhou, Henan, China
Henan Cancer Hospital, Zhengzhou, Hena, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Xiangya Second Hospital of Central South University, Changsha, Hunan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Baotou Cancer Hospital, Baotou, Inner Mongolia, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06797297 on ClinicalTrials.gov

Other trials for Malignant melanoma of the mucosa

Additional recruiting or active studies for the same condition.

See all trials for Malignant melanoma of the mucosa →

← Back to all trials